Sarepta Therapeutics Inc (SRPT) concluded trading on Wednesday at a closing price of $62.47, with 3.77 million shares of worth about $235.74 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -49.98% during that period and on April 03, 2025 the price saw a gain of about 0.90%. Currently the company’s common shares owned by public are about 96.90M shares, out of which, 91.14M shares are available for trading.
Stock saw a price change of -14.28% in past 5 days and over the past one month there was a price change of -39.27%. Year-to-date (YTD), SRPT shares are showing a performance of -48.62% which decreased to -51.35% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $61.53 but also hit the highest price of $173.25 during that period. The average intraday trading volume for Sarepta Therapeutics Inc shares is 1.40 million. The stock is currently trading -24.73% below its 20-day simple moving average (SMA20), while that difference is down -37.26% for SMA50 and it goes to -49.14% lower than SMA200.
Sarepta Therapeutics Inc (NASDAQ: SRPT) currently have 96.90M outstanding shares and institutions hold larger chunk of about 91.28% of that.
The stock has a current market capitalization of $6.06B and its 3Y-monthly beta is at 0.84. PE ratio of stock for trailing 12 months is 26.21, while it has posted earnings per share of $2.38 in the same period. Its PEG reads 0.29 and has Quick Ratio of 3.18 while making debt-to-equity ratio of 0.88. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SRPT, volatility over the week remained 5.51% while standing at 5.10% over the month.
Stock’s fiscal year EPS is expected to rise by 367.11% while it is estimated to increase by 28.36% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on April 02, 2025 offering a Neutral rating for the stock and assigned a target price of $75 to it. Coverage by RBC Capital Mkts stated Sarepta Therapeutics Inc (SRPT) stock as a Sector perform in their note to investors on March 31, 2025, suggesting a price target of $87 for the stock. On February 11, 2025, Deutsche Bank Initiated their recommendations, while on November 27, 2024, Needham Reiterated their ratings for the stock with a price target of $202. Stock get a Sell rating from H.C. Wainwright on November 25, 2024.
